Soleno Therapeutics Inc (NASDAQ: SLNO) kicked off on Friday, down -4.22% from the previous trading day, before settling in for the closing price of $54.08. Over the past 52 weeks, SLNO has traded in a range of $21.75-$59.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
While this was happening, its average annual earnings per share was recorded -77.18%. With a float of $30.60 million, this company’s outstanding shares have now reached $31.68 million.
Let’s look at the performance matrix of the company that is accounted for 42 employees. In terms of profitability, gross margin is 57.25%, operating margin of -3995.07%, and the pretax margin is -3806.27%.
Soleno Therapeutics Inc (SLNO) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Soleno Therapeutics Inc is 28.78%, while institutional ownership is 81.87%. The most recent insider transaction that took place on Oct 21 ’24, was worth 51,416,038. Before that another transaction happened on Oct 07 ’24, when Company’s Rule 144 Affiliate proposed sale 2,522,751 for $49.63, making the entire transaction worth $125,204,132.
Soleno Therapeutics Inc (SLNO) Latest Financial update
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.33 earnings per share (EPS), lower than consensus estimate (set at -0.26) by -0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.75 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -77.18% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.00% during the next five years compared to 24.34% growth over the previous five years of trading.
Soleno Therapeutics Inc (NASDAQ: SLNO) Trading Performance Indicators
Take a look at Soleno Therapeutics Inc’s (SLNO) current performance indicators. Last quarter, stock had a quick ratio of 17.26.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.31, a number that is poised to hit -1.03 in the next quarter and is forecasted to reach -2.54 in one year’s time.
Technical Analysis of Soleno Therapeutics Inc (SLNO)
Soleno Therapeutics Inc (NASDAQ: SLNO) saw its 5-day average volume 0.5 million, a positive change from its year-to-date volume of 0.47 million. As of the previous 9 days, the stock’s Stochastic %D was 10.02%. Additionally, its Average True Range was 2.38.
During the past 100 days, Soleno Therapeutics Inc’s (SLNO) raw stochastic average was set at 60.90%, which indicates a significant increase from 5.13% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 34.08% in the past 14 days, which was lower than the 54.67% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $52.74, while its 200-day Moving Average is $46.83. Nevertheless, the first resistance level for the watch stands at $53.71 in the near term. At $55.63, the stock is likely to face the second major resistance level. The third major resistance level sits at $56.80. If the price goes on to break the first support level at $50.63, it is likely to go to the next support level at $49.46. The third support level lies at $47.54 if the price breaches the second support level.
Soleno Therapeutics Inc (NASDAQ: SLNO) Key Stats
The company with the Market Capitalisation of 2.14 billion has total of 43,117K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -38,990 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -76,620 K.
